Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.


AEMPS: Solicitudes de autorización de comercialización de medicamentos de uso humano. Monográfico de bases legales

Sorry, this entry is only available in Español.


Comments are closed.

FDA approves Ofev to treat idiopathic pulmonary fibrosis
FDA – CDER SBIA Update: New Guidance Documents
FDA approves Esbriet to treat idiopathic pulmonary fibrosis
UK MHRA: EMA public consultation on functional specification for portal and database that will underpin the EU Clinical Trials Regulation (deadline 31 October 2014)
AEMPS – Corrección de la nota informativa: Ácido valproico: nuevas recomendaciones de uso en niñas y mujeres con capacidad de gestación
EMA: Concept paper on the need for revision of the points to consider on the clinical investigation of new medicinal products for the treatment of acute coronary syndrome
UK MHRA Drug Safety Update (Volume 8, Issue 3)
ANSM: Iclusig (ponatinib), médicaments à base de testostérone, médicaments contenant du valproate et dérivés (divalproate de sodium / valpromide): retour d’information sur le PRAC d’octobre 2014
UK MHRA: ‘One stop shop’ for advice on regenerative medicine opening for business
ANSM: Médicaments contenant de la dompéridone: retour sur la réunion de septembre 2014 du CMDh